Atsushi Narita

TL;DR: This work developed ERY974, a whole humanized immunoglobulin G–structured TRAB harboring a common light chain, which bispecifically binds to GPC3 and CD3 and induced a robust antitumor efficacy even against tumors with nonimmunogenic features, which are difficult to treat by inhibiting immune checkpoints such as PD-1 and CTLA-4.

TL;DR: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells as discussed by the authors.

TL;DR: The outline, prospects, and limitations of the common light chain format, which includes one of Chugai's proprietary technologies, termed ART-Ig technology, are introduced and some tips for de-risking the antibody when engineering a T cell redirecting antibody are described.

TL;DR: A three-fold daily ascending dose of a CD3 bispecific construct that targets and cross-reacts with both glypican 3 and CD3 (ERY22) dramatically reduced the peak cytokine levels of IL-6, TNF-α, and IFN-γ, IL-2 as well the clinical severity of CRS.

TL;DR: In this article, an anti-VEGF-D antibody binding to VEGF was obtained and humanizing the antibody while maintaining the activity of the antibody in a system where a cell expressing VEGDF-D is transplanted, and exhibiting lymphangiogenesis inhibiting activity and/or lymphnode metastasis inhibiting action in vivo.